Article
Multidisciplinary Sciences
Piotr Szumowski, Saeid Abdelrazek, Dorota Iwanicka, Malgorzata Mojsak, Monika Sykala, Lukasz Zukowski, Katarzyna Siewko, Agnieszka Adamska, Katarzyna Maliszewska, Anna Poplawska-Kita, Malgorzata Szelachowska, Adam Kretowski, Janusz Mysliwiec
Summary: Dosimetry based on Marinelli's formula is essential for determining the radioiodine activity in adjuvant therapy for thyroid cancer. The retrospective analysis showed that adjusting therapeutic activities of I-131 based on dosimetry measurements can lead to successful outcomes for patients.
SCIENTIFIC REPORTS
(2021)
Review
Oncology
Michele Klain, Emilia Zampella, Carmela Nappi, Emanuele Nicolai, Raffaele Ambrosio, Elena Califaretti, Livia Lamartina, Martin Schlumberger, Desiree Deandreis, Domenico Salvatore, Alberto Cuocolo
Summary: This review summarizes recent advances in functional imaging and theragnosis of DTC, focusing on the use of radioactive iodine for treatment and FDG uptake for diagnosis. It also discusses other potential tracers and technologies that may offer new opportunities in selecting specific imaging modalities or treatments for patients with DTC.
Article
Endocrinology & Metabolism
Bernadette L. Dekker, Mirthe H. Links, Anneke C. Muller Kobold, Linda G. Swart-Busscher, Marleen Kars, Judith A. P. Bons, Adrienne H. Brouwers, Thera P. Links, Anouk N. A. Van der Horst-Schrivers
Summary: This study investigated whether a 4-day low-iodine diet (LID) is sufficient for adequate iodine depletion in differentiated thyroid cancer (DTC) patients preparing for I-131 therapy. The results showed no significant difference in the 24-hour urinary iodine excretion (UIE) between day 4 and day 7 of the LID. On day 4, 72.1% of DTC patients achieved adequate preparation, increasing to 82.0% on day 7. Compared to their regular diet, DTC patients had significantly lower nutrient intake during the LID.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Myat Han Soe, Janet M. Chiang, Robert R. Flavell, Elham Khanafshar, Laura Mendoza, Hyunseok Kang, Chienying Liu
Summary: Patients with radioactive iodine refractory metastatic differentiated thyroid cancer have a poor prognosis. This study aimed to characterize patients with non-iodine-avid disease at diagnosis. The results showed that non-iodine-avid disease is highly prevalent in DTC patients with BVL cancers, particularly with BRAF (V600E) and TERT promoter mutations, and is associated with older age.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Liu Xiao, Wenjie Zhang, Hongmei Zhu, Yueqi Wang, Bin Liu, Rui Huang, Lin Li
Summary: This study investigated the changes in PTH, serum calcium, phosphorus, and 25-OH-VD levels before and after RAI in DTC patients, finding that about one-fifth of patients may experience hypocalcemia at five days post-RAI. Lower baseline pre-RAI serum calcium and PTH levels, as well as negative (TcO4)-Tc-99m (-) thyroid imaging, were identified as risk factors for hypocalcemia at five days post-RAI.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Otorhinolaryngology
Stylianos Monos, Christian Fritz, Jacob Harris, Dominic Romeo, Jinggang J. Ng, Katherine Xu, Benjamin Cooperberg, Alvaro Moreira, Karthik Rajasekaran
Summary: This study assessed and evaluated clinical practice guidelines for radioactive iodine (RAI) in differentiated thyroid carcinoma (DTC), as well as the treatment for radioactive iodine refractory (RAI-R) DTC. The findings revealed a lack of high-quality guidelines in both areas and highlighted the need for more rigorously developed guidelines to guide the use of RAI in DTC and the treatment for RAI-R DTC.
OTOLARYNGOLOGY-HEAD AND NECK SURGERY
(2023)
Review
Endocrinology & Metabolism
Timothy M. Ullmann, Maria Papaleontiou, Julie Ann Sosa
Summary: This review discusses the controversies and difficult decisions in the management of low-risk differentiated thyroid cancer (DTC) and provides recommendations. While overdiagnosis is a concern, the true incidence of DTC has also increased. Treatment options vary, and personalized and nuanced treatment decisions are necessary for clinicians and patients.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Oncology
Xiaoran Mei, Xiaoqin Yao, Fang Feng, Weiwei Cheng, Hui Wang
Summary: This study found that DTC survivors had a slightly increased risk of developing other malignancies after receiving RAI treatment, but the attributable risk proportion associated with RAI was relatively low, indicating a low absolute number of malignancies induced by RAI in DTC survivors. The highest attributable risk proportion of RAI treatment was observed in hematological malignancies, but due to their low incidence among all DTC survivors, the absolute number of hematological malignancies was low.
Article
Otorhinolaryngology
Simran Arjani, Patrick L. Quinn, Ravi J. Chokshi
Summary: The study found that in patients requiring postthyroidectomy ablation, empiric radioactive iodine dosing is a cost-effective strategy that results in more quality-adjusted life-years.
OTOLARYNGOLOGY-HEAD AND NECK SURGERY
(2021)
Review
Otorhinolaryngology
Danielle L. James, Eanna J. Ryan, Matthew G. Davey, Alanna Jane Quinn, David P. Heath, Stephen James Garry, Michael R. Boland, Orla Young, Aoife J. Lowery, Michael J. Kerin
Summary: The study compared the effects of low- and high-activity RAI on long-term cure rates in low- and intermediate-risk thyroid cancer, showing no significant difference in successful ablation and recurrence rates between the two. Therefore, low-activity RAI may be preferred in low- and intermediate-risk DTC due to its similar efficacy but reduced morbidity.
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY
(2021)
Article
Endocrinology & Metabolism
Stephanie Davis, Timothy M. Ullmann, Sanziana Roman
Summary: This review examines the disparities in diagnosis and treatment of patients with differentiated thyroid cancer (DTC) and proposes practical clinical and policy ideas for improving the gap in treatment.
Article
Radiology, Nuclear Medicine & Medical Imaging
Audrey Mauguen, Ravinder K. Grewal, Finn Augensen, Murad Abusamra, Sonia Mahajan, Vetri Sudar Jayaprakasam, Joseph Osborne, Sofia Haque, Bernadette Z. Y. Wong, Ronald A. Ghossein, James Fagin, Heiko Schoder, R. Michael Tuttle, Alan Ho, John L. Humm, Steven M. Larson
Summary: This article introduces a biomarker-based dosimetry method for the rational selection of a treatment activity for patients undergoing radioactive iodine I-131 therapy (RAI) for metastatic differentiated thyroid cancer (mDTC) based on single-timepoint imaging of individual lesion uptake by I-124 PET.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Pharmacology & Pharmacy
Bo Shi, Wenbiao Ma, Hongshuai Pan, Yang Shi, Huan Zhang, Shenghai Xing
Summary: This study evaluated the cost-effectiveness of apatinib and cabozantinib for RAIR-DTC from the perspective of the Chinese healthcare system. The results showed that apatinib is cost-effective compared to placebo, while cabozantinib may not be cost-effective and a reduction in price is warranted.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Endocrinology & Metabolism
Martin Schlumberger, Sophie Leboulleux
Summary: Considerable changes have occurred in the management of differentiated thyroid cancer (DTC) over the past four decades, with improved diagnostic tools and prognostic classifications available. Low-risk patients make up the majority with good outcomes, while high-risk patients require more aggressive treatment and follow-up due to frequent recurrences.
NATURE REVIEWS ENDOCRINOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Minoru Inoue, Yusuke Iizuka, Kiyonao Nakamura, Genki E. Sato, Takashi Mizowaki
Summary: Differentiated thyroid cancer (DTC) is a common malignancy that requires effective prognostic markers and therapeutic targets. This study suggests that the redox state of human serum albumin (HSA) cysteine-34 has potential as a prognostic indicator and therapeutic avenue. In vitro experiments showed that the reduced form of HSA induced cytotoxic effects through ferroptosis. These findings highlight the opportunity for personalized treatment strategies in DTC management.
FREE RADICAL BIOLOGY AND MEDICINE
(2023)
Article
Medical Informatics
Anna M. Sawka, Sharon Straus, Gary Rodin, Richard W. Tsang, James D. Brierley, Lorne Rotstein, Phillip Segal, Amiram Gafni, Shereen Ezzat, David P. Goldstein
BMC MEDICAL INFORMATICS AND DECISION MAKING
(2015)
Article
Hematology
Shane A. Gangatharan, Manjula Maganti, John G. Kuruvilla, Vishal Kukreti, Rodger E. Tiedemann, Mary K. Gospodarowicz, David C. Hodgson, Alex Sun, Richard W. Tsang, Melania Pintilie, Michael Crump
BRITISH JOURNAL OF HAEMATOLOGY
(2015)
Article
Oncology
Anna M. Sawka, Sharon Straus, Gary Rodin, Lineke Heus, James D. Brierley, Richard W. Tsang, Lorne Rotstein, Shereen Ezzat, Phillip Segal, Amiram Gafni, Kevin E. Thorpe, David P. Goldstein
Article
Oncology
Maja V. Maraldo, Bouthaina S. Dabaja, Andrea R. Filippi, Tim Illidge, Richard Tsang, Umberto Ricardi, Peter M. Petersen, Deborah A. Schut, John Garcia, Jayne Headley, Amy Parent, Benoit Guibord, Riccardo Ragona, Lena Specht
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2015)
Article
Oncology
Jacqueline L. Bender, David Wiljer, Anna M. Sawka, Richard Tsang, Nour Alkazaz, James D. Brierley
SUPPORTIVE CARE IN CANCER
(2016)
Letter
Oncology
Anna M. Sawka, Richard W. Tsang, James D. Brierley, Lorne Rotstein, Phillip Segal, Shereen Ezzat, David P. Goldstein
Article
Oncology
Lynn Million, Esther J. Yi, Frank Wu, Rie Von Eyben, Belinda A. Campbell, Bouthaina Dabaja, Richard W. Tsang, Andrea Ng, Lynn D. Wilson, Umberto Ricardi, Youlia Kirova, Richard T. Hoppe
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2016)
Letter
Endocrinology & Metabolism
Anna M. Sawka, James D. Brierley, Richard W. Tsang, Lorne Rotstein, Shereen Ezzat, David P. Goldstein
Article
Oncology
Ezra Hahn, Haiyan Jiang, Angela Ng, Shaheena Bashir, Sameera Ahmed, Richard Tsang, Alexander Sun, Mary Gospodarowicz, David Hodgson
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2017)
Article
Otorhinolaryngology
Jason J. Xu, Eugene Yu, Caitlin McMullen, Jesse Pasternak, Jim Brierley, Richard Tsang, Han Zhang, Antoine Eskander, Lorne Rotstein, Anna M. Sawka, Ralph Gilbert, Jonathan Irish, Patrick Gullane, Dale Brown, John R. de Almeida, David P. Goldstein
JOURNAL OF OTOLARYNGOLOGY-HEAD & NECK SURGERY
(2017)
Article
Oncology
Haowei (Linda) Sun, Eshetu G. Atenafu, Richard Tsang, Vishal Kukreti, Theodore K. Marras, Michael Crump, John Kuruvilla
LEUKEMIA & LYMPHOMA
(2017)
Letter
Biophysics
Umberto Falcone, Haiyan Jiang, Shaheena Bashir, Richard Tsang, Vishal Kukreti, Armand Keating, Michael Crump, John Kuruvilla
BONE MARROW TRANSPLANTATION
(2018)
Article
Oncology
J. L. Hamilton, S. Foxcroft, E. Moyo, J. Cooke-Lauder, T. Spence, P. Zahedi, A. Bezjak, D. Jaffray, C. Lam, D. Letourneau, M. Milosevic, R. Tsang, R. Wong, F. F. Liu
Article
Oncology
B. S. Dabaja, A. D. Zelenetz, A. K. Ng, R. W. Tsang, S. Qi, P. K. Allen, D. Hodgson, U. Ricardi, R. T. Hoppe, R. Advani, P. M. Mauch, L. S. Constine, L. Specht, Y. Li, S. A. Terezakis, A. Wirth, G. Reinartz, H. T. Eich, B. M. P. Aleman, P. Barr, J. Yahalom
ANNALS OF ONCOLOGY
(2017)
Article
Oncology
H. Vulpe, J. Y. Y. Kwan, A. McNiven, J. D. Brierley, R. Tsang, B. Chan, D. P. Goldstein, L. W. Le, A. Hope, M. Giuliani
